Deuterium

Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, General Health, Pharmaceutical, Health, Alopecia areata, International, LinkedIn, Software, CNCE, Medication, DCE, Twitter, Investor, Company, Concert, Webcast, NASDAQ, Deuterium, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.
  • ET to discuss its first quarter 2022 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Green Hydrogen International (GHI) Signs MOU With Hydrogen Optimized for Proposal to Build Gigawatt-Scale Water Electrolyzer Factory in Texas

Retrieved on: 
Wednesday, April 27, 2022
Hydrogen, CEO, Hydrogen internal combustion engine vehicle, GHI, Key, Technology, Benzo(ghi)perylene, Company, McKinsey & Company, MOU, Adoption, GW, Iridium, Deuterium, Oil, Renewable energy

AUSTIN, Texas and OWEN SOUND, ON, April 27, 2022 /PRNewswire/ -- Green Hydrogen International (GHI) and Hydrogen Optimized, a subsidiary of Key DH Technologies Inc., have signed a Memorandum of Understanding (MOU) for the proposed development of a large electrolyzer manufacturing facility in Texas. The factory will produce Hydrogen Optimized's RuggedCell™ water electrolyzers for GHI's planned Hydrogen City project, a previously announced 60 gigawatt (GW) green hydrogen production and salt cavern storage hub to be built in South Texas.

Key Points: 
  • AUSTIN, Texas and OWEN SOUND, ON, April 27, 2022 /PRNewswire/ -- Green Hydrogen International (GHI) and Hydrogen Optimized, a subsidiary of Key DH Technologies Inc., have signed a Memorandum of Understanding (MOU) for the proposed development of a large electrolyzer manufacturing facility in Texas.
  • The factory will produce Hydrogen Optimized's RuggedCell water electrolyzers for GHI's planned Hydrogen City project, a previously announced 60 gigawatt (GW) green hydrogen production and salt cavern storage hub to be built in South Texas.
  • Hydrogen Optimized is a private hydrogen technology company that develops and commercializes large-scale green hydrogen production systems.
  • Hydrogen Optimized seeks to be the first water electrolysis company to supply an aggregate of 10 GW of hydrogen production equipment.

Japan's first laser nuclear fusion company, EX-Fusion raises 130 million JPY in pre-seed round paving way for the development of critical components needed for commercialization of nuclear fusion

Retrieved on: 
Monday, April 18, 2022
Ignition, Carbon, Laser, Chapter Six, Research, National Ignition Facility, Nuclear fusion, Hertz, Neutron, ESG, LFEX, Toyota, Publishing, Efficiency, Hydrogen, Graduate school, GEKKO XII, Technology, Electricity, Temperature, DARPA, University of California, San Diego, Osaka University, Lawrence Livermore National Laboratory, IOP Publishing, NIF, Creation, GPI, ILE, CTSS, Hope, Tritium, University, Deuterium, Institute, Geiger–Nuttall law, Hamamatsu Photonics, Lithium, 3D printing

OSAKA, Japan, April 18, 2022 /PRNewswire/ -- EX-Fusion Inc., the first startup in Japan aimed at commercializing laser based fusion energy, announced on March 31, 2022 that it has closed a pre-seed round funding of 130 million Japanese yen. The pre-seed round was led by ANRI, a Tokyo based venture capital firm, along with Osaka University Venture Capital (OUVC) and was the first company funded within ANRI's latest ESG specific fund.

Key Points: 
  • "We believe that nuclear fusion is the solution for meeting our global energy needs and helping the world reach carbon neutrality by 2050," said Matsuo.
  • "And by focusing our research and development around the fundamental technology related to commercial operation of laser-based nuclear fusion, we can achieve safe and affordable clean energy faster.
  • EX-Fusion is a Japan-based private company aiming to develop the first commercial laser based nuclear fusion reactor for power generation.
  • Our company was established to consolidate the knowledge of laser fusion that has been cultivated in Japan and to realize a commercial laser fusion reactor.

Japan's first laser nuclear fusion company, EX-Fusion raises 130 million JPY in pre-seed round, paving way for the development of critical components needed for commercialization of nuclear fusion

Retrieved on: 
Monday, April 18, 2022
Ignition, Carbon, Laser, Research, National Ignition Facility, Nuclear fusion, Hertz, Neutron, ESG, LFEX, Toyota, Efficiency, Hydrogen, Graduate school, GEKKO XII, Technology, Electricity, Temperature, DARPA, University of California, San Diego, Osaka University, Lawrence Livermore National Laboratory, NIF, Creation, GPI, ILE, Hope, CTSS, Tritium, Multimedia, University, Deuterium, Institute, Hamamatsu Photonics, Lithium, 3D printing

OSAKA, Japan, April 18, 2022 /PRNewswire/ -- EX-Fusion Inc., the first startup in Japan aimed at commercializing laser based fusion energy, announced on March 31, 2022 that it has closed a pre-seed round funding of 130 million Japanese yen. The pre-seed round was led by ANRI, a Tokyo based venture capital firm, along with Osaka University Venture Capital (OUVC) and was the first company funded within ANRI's latest ESG specific fund.

Key Points: 
  • "We believe that nuclear fusion is the solution for meeting our global energy needs and helping the world reach carbon neutrality by 2050," said Matsuo.
  • EX-Fusion is a Japan-based private company aiming to develop the first commercial laser based nuclear fusion reactor for power generation.
  • Our company was established to consolidate the knowledge of laser fusion that has been cultivated in Japan and to realize a commercial laser fusion reactor.
  • Fusion.

Building a Cleaner, Better Future and Enabling America With Kronos Fusion

Retrieved on: 
Wednesday, April 6, 2022
Dream, Radioactive waste, Aircraft, Hazardous waste, Kronos, Disaster, Tritium, Greenhouse, Government, White House, Industry, Deuterium, GLOBE, Helium, Deep learning, Algorithm, Lithium

Kronos Fusion is positioning itself to give the USA dominance in this transformation through its powerful quantum computing algorithms.

Key Points: 
  • Kronos Fusion is positioning itself to give the USA dominance in this transformation through its powerful quantum computing algorithms.
  • Kronos is working to usher in the fusion age because fusion power is good for the Earth and for humanity.
  • Kronos Fusion Energy is dedicated to a clean, green future and a safer, healthier world for humanity, but it's also excited about the potential for fusion energy to enable people in the immediate future.
  • Kronos' launch of its Fusion Energy Simulation Center will create hundreds of U.S. jobs as it runs its deep learning simulations.

LG Display Demonstrates OLED.EX's Evolutionary Experience at 2022 OLED Korea Conference

Retrieved on: 
Thursday, April 7, 2022
OLED, Portable, LG Display, Multimedia, OTT, NYSE, KRX, Tablet, Color, HDR, Research, Conference, LPL, Senior, High dynamic range, View, Light, Industry, Deuterium, Technology, Architecture, COVID-19, Nature, Algorithm, Television, Solution, Immersion, VP, KOREA, News, Speech, Television set, Transparency

SEOUL, South Korea, April 6, 2022 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that Lee Hyeon-woo, Senior Vice President and Head of Life Display Business Group at LG Display, gave a keynote speech under the theme of 'OLED, The Evolutionary Experience' at the 2022 OLED KOREA Conference held in Korea on April 7th.

Key Points: 
  • SEOUL, South Korea, April 6, 2022 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that Lee Hyeon-woo, Senior Vice President and Head of Life Display Business Group at LG Display, gave a keynote speech under the theme of 'OLED, The Evolutionary Experience' at the 2022 OLED KOREA Conference held in Korea on April 7th.
  • Accordingly, LG Display introduced the next-generation OLED.EX TV panel that applies deuterium and personalized algorithms to its groundbreaking organic light-emitting diode pixels to increase brightness by 30%.
  • LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world's leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays.
  • LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam.

Global Quantum Cascade Lasers Market to Reach $462.2 Million by 2026

Retrieved on: 
Thursday, March 24, 2022
CAGR, Gesellschaft mit beschränkter Haftung, Forecasting, Research, Bell Labs, Technology, Laser, Efficiency, C, Players, HHL, Continuous wave, Marketing, VHL, QCL, Laboratory, Geography, Industrial, Electronics, Growth, Quantum cascade laser, Internet, Intelligence, Deuterium, SAN, Bell Laboratories Building (Manhattan), Distributed feedback laser, Productive nanosystems, Chevrolet small-block engine, GIA, COVID-19, Defense, Pet, Health care, Telecommunication, Others

SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Quantum Cascade Lasers - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Quantum Cascade Lasers - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Quantum Cascade Lasers estimated at US$391.1 Million in the year 2022, is projected to reach a revised size of US$462.2 Million by 2026, growing at a CAGR of 4% over the analysis period.
  • This segment currently accounts for a 29.9% share of the global Quantum Cascade Lasers market.
  • The U.S. Market is Estimated at $220.2 Million in 2022, While China is Forecast to Reach $18.7 Million by 2026
    The Quantum Cascade Lasers market in the U.S. is estimated at US$220.2 Million in the year 2022.

Kronos Fusion Energy Looks to Take the Next Steps With Direct Fusion Drive

Retrieved on: 
Monday, March 14, 2022
Direct Fusion Drive, Electricity, DFD, Field line, SUV, U.S. Department of Defense Strategy for Operating in Cyberspace, Solar System, Deuterium, Spacecraft, Radio, GLOBE, Ion, RET, Plasma, White House, Lithium

The Direct Fusion Drive may be edging closer to reality thanks to the work of Kronos Fusion Energy Defense Systems, in conjunction with the U.S. Department of Defense.

Key Points: 
  • The Direct Fusion Drive may be edging closer to reality thanks to the work of Kronos Fusion Energy Defense Systems, in conjunction with the U.S. Department of Defense.
  • "The power generated by a Kronos Fusion Energy Defense System's Direct Fusion Drive can sustain space travel, or the life support of a surface mission, for many years, without reliance on external solar capture or the need to carry huge amounts of fuel," said Brig.
  • Gen. (Ret) Paul E. Owen,CEO of Kronos Fusion Energy Defense Systems.
  • Kronos Fusion technology can exceed the power of even the most ambitious plans to use Nuclear Fission technology as a fuel for space travel."

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

Retrieved on: 
Thursday, February 24, 2022
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Investor, Webcast, Twitter, International, NASDAQ, Medication, DCE, Company, CNCE, Alopecia areata, LinkedIn, Deuterium, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.
  • ET to discuss its fourth quarter 2021 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Retrieved on: 
Thursday, February 3, 2022
Hematological Cancer Research Investment and Education Act, IND, CEO, Safety, Private Securities Litigation Reform Act, Patient, Food, Georgia Institute of Technology College of Computing, MD Anderson Cancer Center, Cancer, Trial of the century, Clinical trial, Poster, Cancer Prevention and Research Institute of Texas, Twitter, Conference, Patent, Biomedicine, Investor, Technology, Research, COVID-19, Collection, Sarcoma, File, SRC, Investigational New Drug, Ewing's sarcoma, Lymphatic system, GLOBE, Acquisition, Deuterium, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug development, Cancer prevention, FDA, Research institute, Emory University, Form 10-K, LinkedIn, Biomedical engineering, Biology, U.S. Securities and Exchange Commission, Nasdaq, Annual report, Fine chemical, Vaccine, Pharmaceutical industry, Salinicola salarius

Her appointment immediately follows Salarius recent strategic expansion into the targeted protein degradation field through its acquisition of SP-3164 and other assets from DeuteRx LLC.

Key Points: 
  • Her appointment immediately follows Salarius recent strategic expansion into the targeted protein degradation field through its acquisition of SP-3164 and other assets from DeuteRx LLC.
  • Our expansion into the targeted protein degradation field marks a seminal moment for Salarius, and I can think of no one better to lead those efforts than Daniela, stated David Arthur, CEO of Salarius Pharmaceuticals.
  • Targeted protein degradation has the potential to transform how we treat cancer, stated Dr. Santiesteban.
  • Targeted protein degradation is a fast-growing field of drug research that takes advantage of the bodys own degradation system to promote the selective elimination of disease-causing proteins.